AXLA Axcella Health Inc.

5.06
+0.08  (+2%)
Previous Close 4.98
Open 4.99
Price To Book 1.57
Market Cap 116,955,398
Shares 23,113,715
Volume 120,737
Short Ratio
Av. Daily Volume 78,737
Stock charts supplied by TradingView

NewsSee all news

  1. Axcella to Present at J.P. Morgan Healthcare Conference

    Presentation and webcast to take place at 11:30 a.m. ET on January 16 Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach

  2. Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones

    Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks Interim data support candidates' potential to become

  3. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  4. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  5. Axcella Presents Data at ASH Annual Meeting

    Preclinical mechanistic data for constituents of AXA4010 demonstrate multifactorial potential of endogenous metabolic modulators (EMMs) on red blood cell, immune and vascular health Axcella Health Inc. (NASDAQ:AXLA), a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b/3 trial to be initiated 2H 2020.
AXA1665
Hepatic encephalopathy

Latest News

  1. Axcella to Present at J.P. Morgan Healthcare Conference

    Presentation and webcast to take place at 11:30 a.m. ET on January 16 Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach

  2. Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones

    Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks Interim data support candidates' potential to become

  3. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  4. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  5. Axcella Presents Data at ASH Annual Meeting

    Preclinical mechanistic data for constituents of AXA4010 demonstrate multifactorial potential of endogenous metabolic modulators (EMMs) on red blood cell, immune and vascular health Axcella Health Inc. (NASDAQ:AXLA), a

  6. Axcella Strengthens Executive Team with Key Addition and Promotion

    Appoints Laurent Chardonnet as Chief Financial Officer Promotes Heidy King-Jones to General Counsel Axcella Health (NASDAQ:AXLA), a biotechnology company pioneering the research and development of novel

  7. Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957

    Completed enrollment in AXA1125 and AXA1957 study in adults with NAFLD Initiated enrollment of AXA1957 study in adolescents with NAFLD Developing AXA1125 and AXA1957 as therapeutic agents for NASH Axcella Health

  8. Axcella Announces Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting

    Axcella Health Inc. (NASDAQ:AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that the